



EDITORIAL

Open Access

Open access, moving to the fore

Kuan-Teh Jeang*

Abstract

Nine years after its founding, *Retrovirology* has moved to the forefront of virology journals in Impact Factor.

In 2004, during the early days of Open Access, I had the opportunity to start *Retrovirology* employing the then “new way” of publishing [1]. *Retrovirology* was not the first journal that I helped found. Ten years earlier, in 1994, I was one of nine editors, led by Dr. Chuan C. Chang, who started the *Journal of Biomedical Science* [2]. The *Journal of Biomedical Science* originated as a subscription-based journal; thus, when *Retrovirology* began I understood the difference between a publishing model based on subscription (readers/subscribing libraries and institutions pay) versus Open Access (authors pay, and all articles are freely accessible by readers).

At the outset, there were two challenges to *Retrovirology's* success. The first was whether Open Access would be a sustainable business model. In those days, this was an unknown. Today, the increasing popularity of journals like *PLoS ONE*, *Nature's Scientific Reports* (www.nature.com/srep/index.html), *Cell Reports* (www.cellreports.com), *Cell and Bioscience* [3], *Journal of the International AIDS Society* (www.jiasociety.org/index.php/jias), and the recent migration of journals such as *EMBO Molecular Medicine* from a subscription to an Open Access format indicate that the latter business model has achieved financial traction, if not overt profitability.

The second challenge was an early notion held by some that Open Access journals would publish lower “quality” science with inherently less “visible” findings. A few contentious colleagues even insisted, “*Retrovirology* will never reach the Impact Factors of the *Journal of Virology*, *Virology*, and the *Journal of General Virology*!” In retrospect, they were wrong; *Retrovirology* achieved and surpassed those metrics. Indeed, in the 2011 tabulation of Impact Factor and Immediacy Index, *Retrovirology* placed ahead of the *Journal of Infectious Diseases*, *AIDS*,

JAIDS, *J Virol.*, *Virology*, *J Gen Virology*; and two established standards of molecular biology and biochemistry, the *Journal of Molecular Biology* and the *Journal of Biological Chemistry* (Figure 1). Of interest, amongst these journals, *Retrovirology* is the only Open Access journal. This means that only in *Retrovirology* are your papers immediately available for all to read, the very day that they are published, in full text form without the readers being encumbered by subscription fees. This Open Access feature may explain the large advantage in Immediacy Index for papers published in *Retrovirology* over the next-ranked journal, the *Journal of Infectious Diseases* (Figure 1).

Impact Factor and Immediacy Index are two of several proxies of a journal's quality, and one should interpret cautiously their meaning [4]. Arguably, a better measure is to ask how a journal's papers have made a difference in its field. In this respect, a significant example can be drawn from six *Retrovirology* papers published in December 2010 that were the first to pivotally correct the then held belief that XMRV was an etiological cause of Chronic Fatigue Syndrome (CFS) [5-10]. In that instance, *Retrovirology's* Open Access format was particularly instrumental in permitting interested individuals, who were not career scientists, to freely, rapidly, and fully access those paradigm-changing peer-reviewed publications.

Increasing data support the absence of inherent reasons for qualitative difference between papers published in subscription versus Open Access journals [11]. In my view, whether a journal moves to the fore is dictated by the diligence and dedication of its editorial board. *Retrovirology's* strong progress forward is owed to the efforts of its board members (<http://www.retrovirology.com/about/edboard>).

Acknowledgements

I thank Andrew Dayton, Mark Wainberg, and John Semmes for critical readings of this editorial. The opinions expressed here are my personal views

Correspondence: kjeang@nih.gov
The National Institutes of Health, Bethesda, MD, USA

<u>Journal</u>	<u>Impact Factor</u>	<u>Immediacy Index</u>
<i>Retrovirology</i>	6.47	2.61
Journal Infectious Dis	6.41	1.23
AIDS	6.25	1.78
Journal of Virology	5.40	1.29
JAIDS	4.43	1.13
Journal of Gen Virology	3.36	0.85
Virology	3.35	1.10
J Int AIDS Society	3.26	0.64
Virology Journal	2.34	0.35
AIDS Res & Hum Retroviruses	2.25	0.69
Current HIV Research	1.75	0.12
Journal Biological Chemistry	4.77	0.95
Journal Molecular Biology	4.00	1.05

Figure 1 Impact factor and immediacy index of *Retrovirology* and the indicated journals. The data are from the 2011 Journal Citation Reports (ISI Web of Knowledge, Thomson-Reuters).

and do not necessary reflect the views of my employer, the National Institutes of Health, USA. Work in my laboratory is funded in part by intramural support from the National Institute of Allergy and Infectious Diseases, NIAID.

Received: 31 July 2012 Accepted: 3 August 2012

Published: 13 August 2012

References

1. Jeang KT: **Retrovirology and young Turks.** *Retrovirology* 2004, **1**:1.
2. Jeang KT: **If You Build It, They Will Come.** *J Biomed Sci* 1996, **3**(2):67-68.
3. Jeang KT: **If you organize, they will join.** *Cell Biosci* 2011, **1**(1):2.
4. Jeang KT: **Impact factor, H index, peer comparisons, and Retrovirology: is it time to individualize citation metrics?** *Retrovirology* 2007, **4**:42.
5. Robinson MJ, Erlwein OW, Kaye S, et al: **Mouse DNA contamination in human tissue tested for XMRV.** *Retrovirology* 2010, **7**:108.
6. Oakes B, Tai AK, Cingoz O, et al: **Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences.** *Retrovirology* 2010, **7**:109.
7. Sato E, Furuta RA, Miyazawa T: **An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR kit is amplified using standard primers for XMRV.** *Retrovirology* 2010, **7**:110.
8. Hue S, Gray ER, Gall A, et al: **Disease-associated XMRV sequences are consistent with laboratory contamination.** *Retrovirology* 2010, **7**(1):111.
9. Smith RA: **Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses.** *Retrovirology* 2010, **7**:112.
10. Stoye JP, Silverman RH, Boucher CA, Le Grice SF: **The xenotropic murine leukemia virus-related retrovirus debate continues at first international workshop.** *Retrovirology* 2010, **7**:113.
11. Bjork BC, Solomon D: **Open access versus subscription journals: a comparison of scientific impact.** *BMC Med* 2012, **10**:73.

doi:10.1186/1742-4690-9-66

Cite this article as: Jeang: Open access, moving to the fore. *Retrovirology* 2012 **9**:66.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

